natgillin/translations-raw huggingface dataset:
Compound of any one of claims 1 to 7 in the treatment, prevention or amelioration of disorders in an animal, which disorder is treated, prevented or ameliorated by activation of an opioid receptor wherein the disorder is preferably selected from the group consisting of pain, diarrhea, or emesis. 
Spoj prema bilo kojem od zahtjeva 1 do 6 naznačen time da je za uporabu kod liječenja, sprečavanja ili ublažavanja poremećaja kod životinje, koji poremećaj se liječi, sprečava ili ublažava pomoću aktivacije opioidnog receptora.
to generate a compound of formula VI in which formulae 
HR P20140005 T1 kako bi se dobilo spoj formule VI
A pharmaceutical composition comprising the isolated antibody of claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji sadrži izolirano antitijelo ili fragment prema bilo kojem od prethodnih patentnih zahtjeva i farmaceutski prihvatljiv nosač.
In one embodiment, the invention is directed to combinations comprising a compound of formula (I): wherein 
HR P20171450 T1 PATENTNI ZAHTJEVI Kombinacija, naznačena time što sadrži spoj formule (I):
A pharmaceutical aerosol solution composition according to claim 1 or 2 wherein the stabilising amount of a mineral acid is an amount of acid equivalent to 1M hydrochloric acid in the range from 0.15 to 0.28 µg/µl. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 1 ili 2 u kojem stabilizirajuća količina mineralne kiseline jest količina kiseline ekvivalentna 1M klorovodične kiseline u rasponu od 0.15 do 0.28 ug/ul.
A method of inhibiting TTR expression in a mammalian cell, the method comprising: (a) contacting the cell with the pharmaceutical composition of claim 1 and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a TTR gene, thereby inhibiting expression of the TTR gene in the cell. 
kontaktiranje stanice s dsRNA prema zahtjevima 1 do 8; i održavanje stanice dobivene u koraku (a) dovoljno dugo vrijeme da se dostigne degradacija mRNA transkripcije TTR gena, te se tako inhibira ekspresija TTR gena u stanici;
R3, R4 are independently selected from hydrogen, SH or Hal, and 
, R4 su neovisno izabrani od vodika, SH ili Hal, i Hal je F, Cl, Br ili I.
The principles of this extraction process as far as they can be maintained in connection with the present invention can be summarized as follows: 
Principi takvog postupka istakanja, ukoliko se mogu zadržati povezani s predmetnim izumom, mogu se sažeti u sljedeće postupke:
shaping the compositions form (a) and (b) to form at least a bilayer extended release matrix formulation; and 
(c) oblikovanje pripravaka iz koraka (a) i (b) da se dobije barem dvoslojna formulacija matrice s produljenim oslobađanjem; i
The pharmaceutical composition for use according to claim 15 or 16 wherein R12 or R42 independently comprise at least one allyl or vinyl moiety, or the pharmaceutical composition of claim 15 or 16 wherein (i) m is a positive integer and R12, R22 and R42, in combination comprise at least two allyl or vinyl moieties or (ii) n is a positive integer and R12, R32 and R42, in combination, comprise at least two allyl or vinyl moieties. 
Farmaceutski pripravak prema patentnom zahtjevu 8 ili 9, gdje (i) m je pozitivan cijeli broj i R12, R22 i R42, u kombinaciji, sadrže najmanje dva alilna ili vinilna ostatka ili (ii) n je pozitivan cijeli broj i R12, R32 i R42, u kombinaciji, sadrže najmanje dva alilna ili vinilna ostatka.
In animal and human tests, buprenorphine has been shown to have both agonist (morphine-like) and (morphine) antagonist properties. 
U ispitivanjima na životinjama i na ljudima se pokazalo da buprenorfin ima i značajke agonista (poput morfina) i značajke antagonista (morfina).
In this embodiment the resiliency of the cup-shaped part 40 may be utilized in the same way as the taps 18 mentioned with the embodiments described above. 
U ovoj izvedbi elastičnost dijela 40 oblika čašice može se iskoristiti na isti način kao i nastavci 18, koji se spominju u gore opisanim izvedbama.
and wherein the cargo moiety comprises a detectable moiety, a therapeutic moiety, a targeting moiety, or a combination thereof. 
i pri čemu kargo-fragment sadrži detektabilni fragment, terapijski fragment, fragment koji ciljno djeluje, ili njihovu kombinaciju.
said composition is obtainable by removing from the unsaponifiable components of the crude tall oil the following components by distillation: 
(b) - navedeni pripravak se može dobiti uklanjanjem iz neosapunjivih komponenata sirovog talovog ulja sljedećih komponenata destiliranjem:
Zn is the atomic number of each element. 
Broj objave europskog patenta:
A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt of said compound, or a compound according to claim 11 or claim 12, or a combination according to any one of claims 13 to 16, or a pharmaceutical composition according to claim 17 or claim 18, for use in a method for treating non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD). 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, ili farmaceutski prihvatljiva sol navedenog spoja, ili spoj u skladu s patentnim zahtjevom 11 ili patentnim zahtjevom 12, ili kombinacija u skladu s bilo kojim od patentnih zahtjeva 13 do 16, ili farmaceutski pripravak u skladu s patentnim zahtjevom 17 ili patentnim zahtjevom 18, naznačeni time što su namijenjeni upotrebi postupku liječenja nealkoholnog steatohepatitisa (NASH) ili bolesti nealkoholne masne jetre (NAFLD).
The apparatus of claim 7, wherein the L2 signaling data includes a Network Information Table, NIT, having an identifier of a physical layer pipe (PLP_id) and an identifier of a C2 system (C2_system_id) corresponding to the transport stream, TS; and wherein a C2 delivery system descriptor includes the identifier of the PLP and the identifier of the C2 system in a TS loop of the NIT maps transport streams to PLPs in data slices of the C2 systems. 
modulaciju okvira signala pomoću ortogonalne modulacijske tehnike u frekvencijskoj domeni (OFDM); i odašiljanje moduliranog okvira signala, gdje deskriptor dostavnog sustava prijenosa uključujući identifikator PLP-a, identifikator sustava prijenosa i aktivno OFDM polje trajanja simbola u TS petlji NIT mapa prenosi tokove do PLP-ova u podatkovnim komadima sustava prijenosa.
The mixture was stirred at 50° C. for 16 hours, and purified by prep LCMS to give compound 8-1. 
Smjesu se miješa 16 sati na 50 "C, te pročisti preparativnim sustavom LCMS kako bi se dobilo spoj 8-1.
The method of claim 7, wherein the carrier is sodium alginate. 
Postupak prema zahtjevu 6, naznačen time da nosač je natrijev alginat.
The compound of claim 1, characterized by the structure of the formula XI: 
DOOR €, 7. Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom XI:
the network-related user data or the address of the first register node (CDNR1, DNDR1) is stored, associated with the hash value, in the hash table of the second register node (CDNR2, DNLR1). 
- = korisnički podaci vezani uz mrežu ili adresa prvog registarskog čvorišta (CDNR1, DNDRI) se pohranjuju, povezani sa hash vrijednošću, u hash tablici drugog registarskog čvorišta (CDNR2, DNLR1).
The method according to claim 1, wherein said composition consists of alpha-tocopheryl acetate and hydrogenated polydecene. 
Pripravak za uporabu u skladu s patentnim zahtjevom 7, koji se sastoji od alfa-tokoferil acetata i hidrogeniranog polidecena.
The method according to claim 1, wherein the at least one additional additive is selected from the group consisting of sorbitol, sorbitan, and mixtures thereof. 
Medicinski uređaj prema zahtjevu 1, naznačen time, da je PEG-sorbitan ester masnih kiselina odabran od sljedećih: Tween"* 20, Tween* 40, Tween" 60 ili Tween" 80.
• at least one loudspeaker 
najmanje jedan zvučnik
The present application provides for a compound of Formula IV, 
Farmaceutski sastav koji sadrži spoj formule IIB:
An agent for the treatment of spinal canal stenosis containing a heterocyclic derivative represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient; 
Sredstvo namijenjeno upotrebi u liječenju stenoze kralježničnog kanala, naznačeno time što sadrži 2-(4-[N-(5,6-difenilpirazin-2-11)-N-izopropilaminojbutiloksi!octenu
A compound of Claim 2 wherein R1 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with up to 3 substituents independently selected from R14; 
je fenil ili 5- ili 6-člani heteroaromatični prsten, pri čemu je svaki izborno supstituiran sa do 3 supstituenta nezavisno izabrana od R14;
the chemical modification comprises the inclusion of a partial sequence of a CMV immediate-early 1 (IE1) gene to the 5' untranslated region of the mRNA; 
(iv) kemijska modifikacija podrazumijeva uključivanje djelomične sekvence neposredno-ranog gena tipa 1 (IE1) CMY u 5' netranslatirajuću regiju iRNK;
The use of a substantially cylindrical tube means that when the latter is being introduced into a hollow cavity with a blind end, such as the vagina, of which the wall is formed by muscle tissue, an tight closure is formed between this wall and the tube, i.e., in the case of the vagina, a closure is created in its deepest part, where the cervix from which the sample is to be taken is located. Because of the relatively large diameter also position in such a blind end is optimised. 
Upotreba uglavnom cilindrične cijevi znači da, kada se ova posljednja uvede u praznu šupljinu koja ima zatvoreni završetak, takvu šupljinu kao što je rodnica, čija stijenka je načinjena od mišićnog tkiva, tijesno se zatvori prostor između te stijenke i te cijevi, to jest u slučaju rodnice zatvoreni prostor se stvara na najdubljem dijelu gdje se nalazi grlić maternice iz kojega se treba uzeti uzorak, Zbog relativno velikog promjera također se optimira i pozicioniranje u takvom zatvorenom završetku.
A compound of Formula (ID) or a stereoisomer or tautomeric form thereof, wherein: 
Spoj s Formulom (IA) [image] ili njegov stereoizomer ili tautomerni oblik, naznačen time što:
After stirring at room temperature for 1 h the crude mixture was partitioned between saturated aqueous citric acid solution (40 mL) and dichloromethane (40 mL). 
Nakon 1 sata miješanja na sobnoj temperaturi sirovu smjesu se razdijeli između zasićene vodene otopine limunske kiseline (40 ml) i diklormetana (40 ml).
Description of the figures: 
Broj objave europskog patenta:
The method of either of claims 1 or 2, wherein the specified percentage is 40%. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što je specificirani postotak 40%.
A conjugate according to claim 7, wherein said cancer is selected among lung, colon, esophagus, ovary, pancreas, skin, gastric, head and neck, bladder, sarcoma, prostate, hepatocellular, brain, adrenal, breast, endometrial, mesothelioma, renal, thyroid, hematological, carcinoid, melanoma, parathyroid, cervix, neuroblastoma, Wilms, testes, pituitary or pheochromocytoma cancers. 
Konjugat prema zahtjevu 7 ili uporaba prema zahtjevu 8, naznačeni time da je navedeni rak odabran od raka pluća, debelog crijeva, jednjaka, jajnika, gušterače, kože, želuca, glave 1 vrata, mokraćnog mjehura, sarkoma, raka prostate, hepatocelularnog raka, raka mozga, raka nadbubrežne žlijezde, dojke, endometrija, mezotelioma, raka bubrega, štitnjače, hematološkog raka, karcinoida, melanoma, paratiroidnog raka, vrata maternice, neuroblastoma, Wilmsovog tumora, raka testisa, raka hipofize ili feokromocitoma.
characterised in that movable or fixed ring eye (10) is managed in a remotely controlled manner and each buoy (1) becomes a mooring when the ring eye (10) is closed. 
naznačen time, da se upravlja pomičnim ili fiksnim uhom (10) na daljinski kontrolirani način, gdje svaka bova (1) postaje vez kada je uho (10) zatvoreno.
The aqueous pharmaceutical suspension according to claim 3, wherein the hydrocolloid gum is, by weight/volume (g/100 mL), 0.23% to 0.45%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što hidrokoloidna guma iznosi, težinski/volumno (g/100 ml), otprilike 0,23 % do otprilike 0,45 %. t>&
The antisense oligonucleotide conjugate according to claim 1, wherein the sequence of the antisense oligomer comprises a contiguous sequence selected from the group consisting of SEQ ID NO 2 and SEQ ID NO 3. 
Antisens oligonukleotidni konjugat u skladu s patentnim zahtjevom 1, naznačen time što sekvenca antisens oligomera sadrži neprekidnu sekvencu odabranu iz grupe koja se sastoji od SEQ ID NO 2 i SEQ ID NO 3.
The immunogenic composition of claim 1, wherein said at least two optimized pol viral polypeptides comprise an amino acid sequence having the sequences set forth in each of SEQ ID NO:12 and 13. 
Cjepivo prema zahtjevu 1, gdje spomenuto cjepivo sadrži spomenuti optimizirani virusni polipeptid koji ima sekvencu amino kiselina prikazanu u SEQ ID NO:9, te gdje spomenuto cjepivo nadalje sadrži:
The method of claim 1 or 2, further comprising operating in a connected mode for one or more first intervals and operating in a dormant mode for one or more second intervals, wherein said first and second OFDM transmissions are performed in the connected mode, and wherein said operating in the dormant mode comprises: 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što dodatno uključuje rad u spojenom načinu rada u jednom ili više prvih intervala i rad u dormantnom načinu rada u jednom ili više drugih intervala, gdje se navedeno prvo i drugo slanje OFDM provodi u spojenom načinu rada, te gdje se navedeni rad u dormantnom načinu rada sastoji u:
It is also obvious that such processes are comparatively complex. 
Očito je, dakle, da su takvi postupci relativno složeni.
In the case of magnetically anisotropic powder materials, the magnetic powder particles are preferably oriented in the matrix or binder so as to determine a preferred direction of magnetization, chosen perpendicular to the engraved, extended surface of the magnetic sheet. 
Kod magnetski anizotropnih praškastih materijala, poželjno je da se čestice magnetskog praška usmjere u matrici ili vezivnom sredstvu kako bi se moglo odrediti poželjno usmjerenje magnetizacije, a to je okomito na nastavak ugravirane površine magnetskog lista.
wherein said bicyclic ring system may be substituted by 1 to 3 groups selected from the group consisting of C1-C6alkyl, substituted C1-C6alkyl, C3-C7cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, -C(O)Ra, -SO2Ra, arylalkyl, -(C1-C3alkyl)aryloxy, aryl, heteroaryl and C1-C4alkoxy, in which each Ra is independently C1-C6alkyl, substituted C1-C6alkyl or unsubstituted C3-C7cycloalkyl; or a pharmaceutically acceptable salt thereof. 
R, je biciklički sustav prstena, kojeg se bira iz skupine koju čine tetrahidroizokinolinil, tetrahidrokinolinil, indolil, dihidroindolil, indazolil, dihidroindazolil, benzotiofenil, benzodiazolil, dihidrobenzodiazolil, benzimidazolil, indolinil, benzotriazolil, pirolopiridinil, benzotiazolil, benzofuranil, dihidrokinazolinil, te pirolopirimidinil; gdje navedeni biciklički sustav prstena može biti supstituiran s 1 do 3 skupine, koje se bira iz skupine koju čine Cy-Csalkil, supstituirani C,-Csalkil, C3-C;cikloalkil, halogen, hidroksil, okso, amid, karboksilna kiselina, -C(O)R,, - SO2R,, arilalkil, (C,-Czalkil)ariloksi, aril, heteroaril i C,-C,alkoksi, gdje je svaki R, neovisno C,-Csalkil, supstituirani C;-Csalkil ili nesupstituirani C3-Crcikloalkil; ili njegova farmaceutski prihvatljiva sol.
The method of claim 5, wherein the trans-(−)-A9-tetrahydrocannabinol composition comprises at least about 99.5% by weight of trans-(−)-A9-tetrahydrocannabinol based on the total amount of cannabinoids. The method of claim 1, wherein the trans-(−)-A9-tetrahydrocannabinol is present in the first composition in an amount from about 0.75 to about 1.25 molar equivalents per molar equivalent of trans-(+)-A9-tetrahydrocannabinol. 
Postupak prema zahtjevima 1 do 4, naznačen time da je trans-(-)-A*-tetrahidrokanabinol prisutan u prvom sastavu u količini od oko 0.75 do oko 1.25 molarnih ekvivalenata, poželjno od oko 0.9 do oko 1.1 molarnih ekvivalenata, još poželjnije od oko 0.95 do oko 1.05 molarnih ekvivalenata i čak još poželjnije oko 1 molarni ekvivalent po molarnom ekvivalentu trans-(+)-A-tetrahidrokanabinola.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as defined in claim 1 . 
Farmaceutski pripravak naznačen time da sadrži farmaceutski prihvatljiv nosač, te kao aktivan sastojak, terapeutski učinkovitu količinu spoja kako je definirano u bilo kojem od zahtjeva 1 do 15.
If DLS measurement reveals a slowly varying component in the composition, the results should be rejected and the measurement should be repeated on a new sample. 
Ako DLS mjerenje otkriva polako varirajuću komponentu u sastavu, rezultati bi trebali biti odbačeni i mjerenje bi trebalo ponoviti na novom uzorku.
Growth inhibition from start of treatment was calculated by comparison of the mean changes in tumour volume for the control and treated groups, and statistical significance between the two groups was evaluated using a Students t test. 
Inhibicija rasta od početka studije izračunata je u usporedbi sa promjenom srednje vrijednosti volumena tumora u kontrolnim i liječenim grupama, a statistička značajnost između skupina procijenjena je Studentovim # testom.
The transdermal delivery device of any one of claims 1 to 3, wherein the microspheres further comprise a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly (E-caprolactones), polyanhydrides, albumin, blends and copolymers thereof and mixtures thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da mikrosfere nadalje sadrže polimer odabran iz skupine koja se sastoji od poliestera, polietera, poli (ortoestera), polisaharida, ciklodekstrina, citosana, poli (Z-kaprolaktona), polianhidrida, albumina, njihovih mješavina i kopolimera i njihovih smjesa.
A compound according to claim 6 that is (4-cyclopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone dihydrochloride. 
Spoj u skladu sa zahtjevom 6, naznačen time, da je (4-ciklopropil-piperazin-1-il)(4-morfolin-4-ilmetil-fenil)- metanon dihidroklorid.
This is in particular the case in embodiments of the invention where the starting liquid comprises maltose and/or maltotriose, for example in embodiments of the invention where the starting liquid comprises a malt extract and/or wort. 
Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time što početna tekućina sadrži ekstrakt žitarice i/ili ekstrakt slada i/ili sladovinu i/ili voćni sok s visokim udjelom šećera, kao što je sok od jabuka ili sok od kruške.
• a scent carrying material (33), 
materijal (33) koji nosi miris, *
The immunosuppressive effects of rapamycin have been disclosed in FASEB 3, 3411 (1989). 
Imunosupresivni učinci rapamicina objavljeni su u FASEB 3, 3411 (1989).
contacting in vitro the cell with the dsRNA of any one of claims 1 to 7; and 
kontaktiranje stanice s dsRNA prema zahtjevima 1 do 8; i
an intra prediction unit (150) configured to determine an intra prediction mode, to generate reference pixels corresponding to unavailable reference pixels, to adaptively filter the reference pixels according to the intra prediction mode, and to generate a prediction block using the reference pixels determined by the intra prediction mode; 
dekoder rezidualnog signala (220) konfiguriran za vraćanje rezidualnog bloka iz kvantiziranih rezidualnih koeficijenata; generator referentnih piksela (240) konfiguriran za generiranje referentnih piksela koji odgovaraju nedostupnim referentnim pikselima i za adaptivno filtriranje referentnih piksela u skladu s intrapredikcijskim režimom;
A method for generating a human immunoglobulin heavy and/or kappa light chain variable domain sequence comprising the steps of: 
(a) teški lanac koji sadržava varijabilnu domenu humanog imunoglobulina i nepromjenjivu regiju imunoglobulina miša i/ili
This solution is added with a solution of 1 equivalent (10 mmols) of intermediate (2) in acetonitrile and stirred at room temperature until a precipitate forms (4 hours). 
je otopljen u vodi s 4 ekvivalenta K>CO; Ta otopina je dodana otopini 1 ekvivalenta (10 mmol) međuprodukta (2) u acetonitrilu i miješana je pri sobnoj temperaturi do nastanka taloga (4 sata).
in the form of diastereoisomeric mixture (S,R+RR) and optionally separating said compound of formula Va (S,R+R,R) into the single diastereomer Va (S,R) and the single diastereomer Va (R,R). 
VaiBRURB) u obliku dijasteroizomer smjese (S, R+R, R) i po želji, odvajanje navedenog spoja formule Va (S, R, R, R) na zaseban dijasteromer Va (S, R) i zaseban dijasteromer Va (R, R).
The compound for use in a method of treatment or the use of claim 18, wherein: 
Spoj za uporabu u postupku liječenja prema zahtjevu 11 ili uporaba prema zahtjevu 11, naznačen(a) time, da:
The extended release dosage form of claim 9, wherein the opioid analgesic is selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing. 
Oblik doziranja sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 22, naznačen time da je opioidni analgetik odabran iz skupine koja sadrži kodein, morfin, oksikodon, hidrokodon, hidromorfon, ili oksimorfon ili njihove farmaceutski prihvatljive soli, hidrati i solvati, te bilo koje smjese prethodno navedenih analgetika.
The most preferable antibody according to the present invention is a complete human monoclonal antibody including a heavy chain (H-chain) represented by the amino acid sequence of SEQ ID NO:6 and a light chain (L-chain) represented by the amino acid sequence of SEQ ID NO:8. 
Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 3, naznačen/o time, da obuhvaća: a) jaki lanac (H-lanac) koji sadrži aminokiselinsku sekvencu od SEQ ID NO:6; 1 b) slabi lanac (L-lanac) koji sadrži aminokiselinsku sekvencu od SEQ ID NO:8.
The method of claims 18 to 19, wherein the liquid coating formulation used to form an absorptive layer and/or a topcoat has a solid content of 10 to 80 wt.-%, preferably of 30 to 60 wt.-%, and more preferably of 45 to 55 wt.-% based on the total weight of the formulation. 
Postupak prema zahtjevima 17 ili 18, naznačen time da tekuća formulacija premaza koji se koristi za dobivanje apsorpcijskog sloja i/ili završnog premaza koji ima sadržaj krutih tvari od 10 do 80 tež.-%, poželjno od 30 do 60 tež.-%, i poželjnije od 45 do 55 tež.-% u odnosu na ukupnu težinu formulacije.
The formulation according to claims 10 or 11 characterized by having a melting temperature of 36 ± 3 °C or equal to 36 ± 2 °C. 
Formulacija u skladu s patentnim zahtjevima 10 ili 11, naznačena time, da ima temperaturu taljenja 36 ± 3 °C ili jednaku 36 ± 2 °C.
or two R9 groups taken together with the carbon atoms to which they are attached form a fused ring; and 
ili dvije skupine Ro uzete zajedno sa ugljikovim atomom za koji su vezane čine spojeni prsten; i
A peptide according to any one of claims 1 to 3 or an activated cytotoxic T lymphocyte according to claim 10 for use in the treatment of cancer. 
Terapijski učinkovita količina farmaceutskog sastava prema bilo kojem od prethodnih zahtjeva 1 do 8 za uporabu u liječenju karcinoma kod pacijenata.
reducing a compound according to formula (5), or salt thereof, to obtain a compound according to formula (1), or salt thereof. 
A i će Rai Eh gdje RI je vodikova ili dušikova zaštitna skupina, kako bi se dobio spoj formule (1) ili njegova sol.
The method of clause 50, wherein the skeletal muscular disorder and diseases are selected from the group consisting of skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. 
Uporaba prema patentnom zahtjevu 11, naznačena time što su poremećaji i bolesti skeletnih mišića izabrani iz grupe koju čine zamor skeletnog mišića, zamor skeletnog mišića induciran pojačanom fizičkom aktivnošću, mišićna distrofija, poremećaji bešike 1 inkontinencija.